Revolution Medicines, Inc. Contract Liability (Deferred Revenue)
Revolution Medicines, Inc. (RVMD) had Contract Liability (Deferred Revenue) of $0 as of 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-02-26
- 2023-12-31: Contract with Customer, Liability, Current $0.00.
- 2023-09-30: Contract with Customer, Liability, Current $0.00.
- 2023-06-30: Contract with Customer, Liability, Current $0.00.
- 2023-03-31: Contract with Customer, Liability, Current $1.43M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-06 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.43M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $4.46M 10-K · filed 2024-02-26 |
| 2022-09-30 | $9.69M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $9.69M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $11.43M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $12.36M 10-K · filed 2023-02-27 |
| 2021-09-30 | $12.66M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $8.34M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $9.96M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $12.11M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |